Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via Google Scholar Articles by Bhanji, N. H. Articles by Gauthier, S. Search for Related Content PubMed Citation Articles by Bhanji, N. H. Articles by Gauthier, S. Dementias (General)

Emergent Complications Following Donepezil Switchover to Galantamine in Three Cases of Dementia With Lewy Bodies

Received May 3, 2004; revised June 28, 2004; accepted June 29, 2004. From the Clinical Psychopharmacology Unit, Allan Memorial Institute, McGill University Health Centre, 1025 Pine Avenue W., Montreal, Qc Canada H3A 1A1. Department of Psychiatry, McGill University, 1033 Pine Avenue W., Montreal, Quebec, Canada H3A 1A1. McGill Centre for Studies in Aging, LaSalle, Montreal, Quebec, Canada. Address correspondence to Bhanji, Fellow, Clinical Pharmacology Unit, Allan Memorial Institute, McGill University Health Centre, 1025 Pine Avenue W., Montreal, Qc Canada H3A 1A1; nadeem.bhanji{at}mail.mcgill.ca (E-mail).

ABSTRACT

Delayed disease progression and symptomatic improvement occur with cholinesterase inhibitors (ChEIs) in dementia with Lewy bodies (DLB). In this study, complications (insomnia, dyskinesias, agitation, and delirium) occurred in three patients switched from donepezil to galantamine. The authors describe evidence-based recommendations for ChEI switchover in DLB.

Get information about faster international access.

Privacy Policy

Copyright © 2005 American Neuropsychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us